Arovella Therapeutics (ASX:ALA) FCF Yield % : -4.03 (As of Dec. 14, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Arovella Therapeutics's Trailing 12-Month Free Cash Flow is A$-7.04 Mil, and Market Cap is A$174.80 Mil. Therefore, Arovella Therapeutics's FCF Yield % for today is -4.03%.

The historical rank and industry rank for Arovella Therapeutics's FCF Yield % or its related term are showing as below:

ASX:ALA' s FCF Yield % Range Over the Past 10 Years
Min: -103.55 Med: -19.83 Max: -3.5
Current: -4.03

During the past 13 years, the highest FCF Yield % of Arovella Therapeutics was -3.50%. The lowest was -103.55%. And the median was -19.83%.

ASX:ALA's FCF Yield % is ranked better than
72.13% of 1507 companies
in the Biotechnology industry
Industry Median: -13.02 vs ASX:ALA: -4.03

Arovella Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was -48,544.44%.

Arovella Therapeutics FCF Yield % Historical Data

The historical data trend for Arovella Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics FCF Yield % Chart

Arovella Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Yield %

Get a 7-Day Free Trial

-62.17

-14.81

-44.36

-15.06

-4.79

Arovella Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Yield %	Get a 7-Day Free Trial															-58.96	-33.92	-17.74	-5.11	-5.94

Competitive Comparison of Arovella Therapeutics's FCF Yield %

For the Biotechnology subindustry, Arovella Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arovella Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's FCF Yield % falls into.

Arovella Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Arovella Therapeutics's FCF Yield % for the fiscal year that ended in Jun. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-7.043	/	147.0784
	=	-4.79%

Arovella Therapeutics's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-4.369	*	2	/	147.0784
	=	-5.94%

Arovella Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Arovella Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

E4NA:Germany

Address

84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines